# Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

> **NCT01826981** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 359 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** LDV/SOF
- **DRUG:** SOF
- **DRUG:** RBV
- **DRUG:** Peg-IFN
- **DRUG:** GS-9669
- **DRUG:** VEL

## Key facts

- **NCT ID:** NCT01826981
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2015-03
- **Final completion:** 2015-05
- **Target enrollment:** 359 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01826981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01826981, "Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01826981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*